AI-ACCELERATED DRUG DISCOVERY
Company expands team and advisory board to accelerate AI-driven drug discovery innovation
Receptor.AI is pleased to announce the expansion of its U.S. presence by establishing a new headquarters in Boston, Massachusetts, while maintaining its existing headquarters in London, United Kingdom. This strategic move positions the company at the epicenter of the United States' biotech and pharmaceutical industry, enhancing our ability to collaborate with leading organizations and innovate within a dynamic ecosystem.
"Expanding to Boston allows us to engage more closely with our U.S. partners and become an integral part of a vibrant biotech community," said Alan Nafiiev, CEO of Receptor.AI. "We are excited to contribute to the groundbreaking work happening here and to foster new collaborations that will advance the future of healthcare."
As part of this expansion, Receptor.AI has grown its team to 35 members, bringing together a diverse group of experts in artificial intelligence, drug discovery, and biomedical research. This talented team is dedicated to pushing the boundaries of what's possible at the intersection of AI and healthcare.
In addition, we have strengthened our advisory board by welcoming distinguished industry veterans who have successfully brought numerous drugs to market. Their extensive experience in drug discovery and development will be invaluable in aligning our technologies with industry needs and enhancing our competitive advantage.
"Having these seasoned professionals on our advisory board is a significant asset," added Nafiiev. "Their insights will guide us in refining our solutions and expanding our impact in the biotech sector."
Receptor.AI looks forward to engaging in cutting-edge research and development collaborations with innovative organizations in Boston and across the globe. Our new headquarters in Boston not only signifies our commitment to the U.S. market but also underscores our mission to revolutionize drug discovery through advanced AI technologies.
For more information about our relocation and opportunities for collaboration, please contact us.
